reports
Journey Medical Corp: 1 director
A director at Journey Medical Corp bought 33,000 shares at 2.980USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
6 directors gave away/sold after exercising options/bought/sold
Six Directors at Dermira Inc gave away/sold after exercising options/bought/sold 78,753 shares at between 0.000USD and 8.540USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
Dermira Announces “Life Unfolds†Direct-to-Consumer Campaign to Hi...
Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth New multichannel consumer campaign will feature QBREXZA patientsCampaign to drive consumer awareness of QBREXZAQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as excessive underarm sweating MENLO PARK, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical d...
Dermira Announces Closing of Public Offering of Common Stock and Full ...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of its previously announced underwritten public offering of 11,283,019 shares of its common stock, including 1,471,698 shares sold upon full exercise...
Dermira to Present at the Cowen and Company 39th Annual Health Care Co...
Dermira to Present at the Cowen and Company 39th Annual Health Care Conference MENLO PARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Cowen and Company 39th Annual Health Care Conference on Tuesday March 12, 2019 at 9:20 a.m. ET. A live audio webcast and archive of the present...
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating...
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis New analysis from ATMOS-1 and ATMOS-2 Phase 3 studies illustrates efficacy across broad range of patient populations Two additional analyses from ARIDO open-label extension study describe long-term safety and efficacy for up to 44 weeks of ...
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results an...
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for approximately 76% of total U.S. commercial livesEntered into option and license agreement with Almirall for rights to lebrikizumab in EuropeLebrikizumab topline Phase 2b data expected in second half of March MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company ...
Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinica...
Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced that new post-hoc analyses from its glycopyrronium tosylate (QBREXZA™ (glycopyrronium) cloth) clinical program will be presented in poster format at the 77th ...
Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZAâ„¢ (glyco...
Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis - Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis- Results will inform potential development plans for QBREXZA in primary palmar hyperhidrosis- Findings from the study are expected in the second half of 2019 MENLO PARK, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by deliver...
Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Con...
Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference MENLO PARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday February 28, 2019 at 11:30 a.m. ET. A live audio webcast and archive of the prese...
Dermira to Report Fourth Quarter 2018 Results and Host Conference Call...
Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019 MENLO PARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report financial and operating results for the quarter ended December 31, 2018 after market close on Tuesday, February 26, 2019. The company will host a conference call and an audio webcast at 1:30 p.m. Pa...
Almirall and Dermira Enter into Option and License Agreement for Europ...
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe- Dermira to receive an option fee of $30 million- Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data expected by early April 2019 BARCELONA, Spain and MENLO PARK, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME: ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that the companies have ente...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MENLO PARK, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on December 10, 2018, the company granted inducement awards to four new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employm...
Dermira Enters into Credit Facility with Athyrium Capital Management
Dermira Enters into Credit Facility with Athyrium Capital Management Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of a $125 million credit facility with funds managed by Athyrium Capital Management, LP, a lea...
Dermira to Present at Evercore ISI HealthCONx Conference
Dermira to Present at Evercore ISI HealthCONx Conference MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the Evercore ISI HealthCONx Conference. Location: Boston, MAPresentation date: Tuesday November 27, 2018Presentation time: 2:00 p.m. ET A live audio webcast and archive of t...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on November 7, 2018, the company granted inducement awards to seven new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employm...
Dermira Reports Third Quarter 2018 Financial Results
Dermira Reports Third Quarter 2018 Financial Results Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended September 30, 2018 and provided an update on the launch of QBREXZA™ (glycopyrronium) cloth and the lebrikizumab clinical development program...
Dermira to Report Third Quarter 2018 Results and Host Conference Call ...
Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018 MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report financial and operating results for the quarter ended September 30, 2018 after market close on Wednesday, November 7, 2018. The company will host a conference call and an audio webcast at 1:30 p.m. ...
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Ev...
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the completion of patient enrollment in the Phase 2b dose-ranging study e...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MENLO PARK, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on October 8, 2018, the company granted inducement awards to nine new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employmen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.